Gynecologic Cancer CPG Mini-Module – Single agent immunotherapy for Cervical Cancer and Combination Therapy for Mismatch Repair-Proficient (pMMR) Endometrial Cancer

The SITC Cancer Immunotherapy Guidelines Webinars connect clinicians with leading experts in the field and provide education about the evidence- and consensus-based recommendations in the clinical practice guidelines. To complement the advanced live webinar series, three on-demand, mini modules will assist learners in applying lessons learned on specific topics within the use of immunotherapy in their own practices and locate additional resources to continue their education.   

Claire Friedman, MD, of Memorial Sloan Kettering Cancer Center presents two case studies comparing and contrasting single-agent immunotherapy and immunotherapy-based combination therapy for gynecologic cancers. The first study presented addresses pembrolizumab monotherapy for recurrent high-risk HPV-positive cervical cancer, and the second presentation discusses the use of the tyrosine kinase inhibitor lenvatinib plus pembrolizumab to treat recurrent pMMR endometrial cancer. Dr. Friedman presents the relevance of the current guidelines to these cases, key studies supporting the recommendations, clinical benefits and risks associated with single agent therapies versus combination therapies, and future challenges facing the immuno-oncology field for gynecologic cancers. Management of adverse events associated with targeted therapies and/or immunotherapies is also addressed. Dr. Friedman, Dr. Bajpai, and Dr. Odunsi conclude the Mini-Module by discussing practical approaches to promote patient tolerance of lenvatinib.

Run time: Approximately 15 minutes

Target Audience 

Clinicians and advanced practice providers who treat cancer patients are the target audience, including community physicians, oncologists, emergency room physicians, disease specialists, registered nurses, nurse practitioners, pharmacists, physician assistants and radiologists. 

SITC Online Education Disclaimer 

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

The Quick Education Modules are part of the Cancer Immunotherapy Clinical Practice Guidelines Advanced Webinar Series supported, in part, by grants from Amgen and Merck & Co., Inc. (as of 09/07/2023). 

The SITC Clinical Practice Guidelines are produced and funded solely by SITC. No outside funding is received for the development of the manuscripts.